• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2022 Oct 19. doi: 10.2174/1871525721666221019095218. Online ahead of print.ABSTRACTObstructive hypertrophic cardiomyopathy results from asymmetric septal hypertrophy which eventually obstructs the outflow of the left ventricle. Obstructive hypertrophic cardiomyopathy is linked to mutations in genes that encode for sarcomere proteins including actin, &#946:myosin heavy chain, titin, and troponin. The mutations lead to structural abnormalities in myocytes and myofibrils causing conduction irregularities and abnormal force generation. Obstructive hypertrophic cardiomyopathy is a chronic...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - October 24, 2022 Category: Cardiology Authors: Ma'Lik Woodland Rami A Al-Horani Source Type: research

Resolution of left ventricular thrombus with apixaban in a patient with hypertrophic cardiomyopathy.
Abstract Anticoagulation with warfarin is the main treatment of intracardiac thrombus. While novel oral anticoagulants (NOACs) have been approved by the US Food and Drug Administration (FDA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF), they are not indicated for resolution of intracardiac thrombus. The case of a 60-year-old woman with left ventricular (LV) thrombus secondary to hypertrophic cardiomyopathy and AF is described in the present report. Indications for oral anticoagulation were AF and LV thrombus. Thrombus was dissolved after 1 month of apixaban treatment. To the best of ...
Source: Turk Kardiyoloji Dernegi arsivi - May 31, 2016 Category: Cardiology Authors: Kaya A, Hayıroğlu Mİ, Keskin M, Tekkeşin Aİ, Alper AT Tags: Turk Kardiyol Dern Ars Source Type: research